Compare AbCellera Biologics Inc (ABCL) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Riot Platforms Inc — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Riot Platforms Inc trades at $20.94 (market cap $8.01B). The key difference: Riot Platforms Inc is far larger — about 3.4× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | RIOT | |
|---|---|---|
Market Cap | $2.35B | $8.01B |
Sector | Health | Technology |
52-Week High | $8.12 | $28.67 |
52-Week Low | $2.78 | $11.03 |
Enterprise Value | $1.99B | $8.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
RIOT trades at $22.87, up 3.44% today, but technical indicators signal a bearish trend with resistance at $24. The company reported a net loss of $663.18 million in 2025 with negative cash flow from operations, though revenue reached $647.44 million. Recent news highlights volatility tied to Bitcoin price swings and a strategic pivot toward high-performance computing data centers, including a partnership with Terrestrial Energy for nuclear-powered facilities.
Wall Street analysts remain overwhelmingly bullish with a 94% buy rating and $27.83 consensus price target, but high valuation multiples and persistent losses pose significant risks. Investment appeal hinges on successful execution of the AI data center strategy amid competitive and regulatory pressures in the energy-intensive mining sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
